07:08 AM EDT, 04/08/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) said Tuesday that it has selected Cardinal Health ( CAH ) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix for the treatment of prostate cancer in the US.

The company said it wants to enable availability across a wide range of US locations following the recent US Food and Drug Administration approval of Gozellix and in preparation for its commercial launch during the first half of 2025.

Cardinal Health ( CAH ) will operate as a strategic radiopharmacy distributor for Gozellix alongside Telix's in-house radiopharmacy network, the company said.